CI-1029
CI-1029 is a HIV-1 protease inhibitor with a human IC50 of 0.11 nM. CI-1029 inhibits both wild-type and mutant HIV proteases, and exhibits antiviral activity against HIV and multiple drug-resistant HIV strains, with an EC50 of 6.31 μM in the presence of 30% human serum. CI-1029 can be used in studies related to HIV infection and acquired immunodeficiency syndrome (AIDS).
For research use only. We do not sell to patients.
- CAS No.: 207736-05-8
- Formula: C28H37NO4S
- Molecular Weight:483.66
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HIV-1 Protease 0.11 nM (IC50) |
In Vitro
CI-1029 (60 min) potently inhibits purified HIV-1 protease with an IC50 of 0.11 nM and a Ki of 0.11 nM[1].
CI-1029 protects HIV-IIIB-infected CEM cells with an EC50 of 0.20 μM and has low cytotoxicity in uninfected CEM cells with a TC50 of 210 μM, yielding a therapeutic index of 1000[1].
CI-1029 protects HIV-infected cells in the presence of 30% human serum with an EC50 of 6.31 μM[1].
CI-1029 retains potent activity against multiple protease-resistant HIV strains in PBMCs, with a fold increase in EC50 of ≤2 compared to wild-type virus[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
Chemical Information
-
CAS No. 207736-05-8
-
Molecular Weight 483.66
-
Formula C28H37NO4S
-
SMILES
NC(C=C1)=CC=C1CC[C@]2(CC(O)=C(C(O2)=O)SC3=C(C=C(C(C)=C3)CO)C(C)(C)C)C(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)